Magenta Therapeutics, Inc.
COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
Last updated:
Abstract:
The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.
Status:
Application
Type:
Utility
Filling date:
21 Jan 2020
Issue date:
17 Sep 2020